CD8A and myeloid sarcoma: In Figure 2A, representative plots depict the progressive drop of frequencies of subpopulations of CD8 T cells (CD161hi CCR6+) in an MS patient during DMF treatment, while Figure 2B shows the cumulative data with the significant drop of the T-cell subset at T2 (p < 0.001).